AIOMEGA® to Present Six Studies on Adaptive Airway Therapy Device

The AIO Breathe platform aims to redefine sleep apnea treatment across the lifespan.

Apr. 10, 2026 at 11:21pm

Got story updates? Submit your updates here. ›

A ghostly, translucent X-ray image revealing the internal structure of an adaptive sleep apnea therapy device, conceptually illustrating the advanced technologies behind the AIO Breathe platform.The AIO Breathe platform's advanced imaging and robotic technologies aim to redefine airway therapy and support long-term health outcomes for sleep apnea patients.Tyler Today

AIOMEGA®, a medical device company in Texas, announced that its founder Dr. Raghavendra V. Ghuge and co-author Advait R. Ghuge will deliver six peer-reviewed presentations this summer on the AIO Breathe platform, which integrates advanced technologies to provide effective, non-surgical treatment options for sleep apnea in both pediatric and adult patients.

Why it matters

The AIO Breathe platform represents a new approach to airway management, offering a single adaptive device that can treat sleep apnea across the lifespan from childhood through adulthood. By combining advanced technologies, the device aims to provide effective, non-surgical treatment options that address both the immediate symptoms of sleep apnea as well as the long-term impacts on growth, development, cognition, and athletic performance in pediatric patients.

The details

The AIO Breathe platform integrates several key technologies to achieve multi-level airway remodeling, including AAVOAT, TAVMLR® real-time airflow optimization, CBCT-based airway analysis, and robotic precision execution of patented algorithms. For pediatric patients ages 6-17, the AIO Breathe Pediatric (PDS) device is designed to provide immediate sleep apnea control while also supporting the natural growth and development of the craniofacial complex. Preliminary clinical observations suggest the pediatric device can improve growth trajectories, behavioral and cognitive function, athletic performance, and overall quality of life.

  • The presentations will be delivered this summer at the AADSM Annual Meeting, AASM SLEEP 2026, and the Southern Sleep Society conference.

The players

Raghavendra V. Ghuge, MD, DABSM, FAASM, MBA

Founder and Chief Medical Officer of AIOMEGA®, the medical device company behind the AIO Breathe platform.

Advait R. Ghuge, BS

Co-author on the presentations and collaborator with Dr. Ghuge at AIOMEGA®.

AIOMEGA®

A medical device innovation company headquartered in Tyler, Texas, specializing in adaptive airway therapy and robotic precision oral appliance technology.

Got photos? Submit your photos here. ›

What they’re saying

“With AIO Breathe, we are establishing a new paradigm — life-long airway management of OSA — a single adaptive platform that grows with the patient from childhood through adulthood.”

— Raghavendra V. Ghuge, MD, DABSM, FAASM, MBA, Founder and Chief Medical Officer, AIOMEGA®

The takeaway

The AIO Breathe platform represents a breakthrough in sleep apnea treatment, offering a single adaptive device that can address the condition across a patient's lifespan. By integrating advanced technologies, the device aims to provide effective, non-surgical options that improve both immediate symptoms and long-term health outcomes, particularly for pediatric patients.